Summary & Overview
HCPCS J0567: Injection, Cerliponase Alfa, 1 mg
HCPCS Level II code J0567 bills for the administration of cerliponase alfa, a 1 mg dose of an enzyme replacement therapy used in specialized treatment protocols. This code is significant nationally because it represents a high-cost, specialized pharmaceutical therapy commonly administered in hospital outpatient departments, infusion centers, or specialty clinics. Accurate coding affects coverage determinations, prior authorization workflows, and hospital and clinic reimbursement for complex drug therapies.
Key payers in the scope of this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J0567 denotes, the clinical context for cerliponase alfa administration, and the payer landscape that typically governs coverage and payment. The publication covers benchmarks and billing considerations, relevant policy updates affecting high-cost biologics, and clinical context that informs site-of-service and utilization patterns. Data on associated taxonomies, ICD-10 diagnoses, related codes, and detailed modifier use are noted where available; if specific items are not in the input, the summary indicates that data is not available.
Billing Code Overview
HCPCS Level II code J0567 represents injection, cerliponase alfa, 1 mg. This code is used for billing the administration of cerliponase alfa, a recombinant enzyme replacement therapy.
-
Service type: Drug administration (intravenous or intrathecal depending on clinical protocol)
-
Typical site of service: Hospital outpatient department, infusion center, or specialty clinic providing enzyme replacement therapy
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A pediatric patient with confirmed neuronal ceroid lipofuscinosis type 2 (CLN2) presents for scheduled enzyme replacement therapy with cerliponase alfa. The child is transported to an outpatient infusion center or hospital outpatient department where a multidisciplinary team (pediatric neurology, infusion nursing, pharmacy, and anesthesia if needed) coordinates the treatment. Prior to infusion, baseline neurologic assessment, weight verification, and device inspection are completed. Cerliponase alfa is administered via intracerebroventricular (ICV) infusion through an implanted reservoir and catheter (e.g., Ommaya reservoir) by trained personnel; sterile technique and neurocritical monitoring are maintained throughout. Post-infusion observation includes neurologic checks and monitoring for infusion reactions; documentation records lot number, amount administered in milligrams, route, date/time, and any modifiers applicable for billing. Typical site of service is an outpatient infusion center, hospital outpatient department, or ambulatory surgery center capable of ICV device access and pediatric monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unspecified | Rarely used; avoid if more specific modifier applies |
22 |